ANA, a third-generation, nonsteroidal, highly selective aromatase inhibitor that is widely used clinically and has been shown to be safe in a small clinical trial in PAH patients [13], had therapeutic effects in both male and female obese mice. Here, CYP19A1 is linked to pulmonary arterial hypertension.